Diurnal is now Neurocrine UK

Welcome to Diurnal

A global specialty pharmaceutical company focused on chronic endocrine diseases

Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

bio image

Overview

Neurocrine is committed to transparency in its interactions. Neurocrine commits to following relevant pharmaceutical codes and has published details of its transfers of value to healthcare organisations. Where individual countries have other transparency regulations, Neurocrine's declarations for these can be found in the Transparency dropdown menu on a country-specific basis. Disclosures prior to 2025 are reported under the legacy name Diurnal.

Neurocrine Group Ltd (Company Number: 09846650) and its subsidiary, Neurocrine UK Ltd (Company Number: 05237326) are companies registered in England and Wales. Registered Offices: Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ, UK.